Dr. Evans on Challenges of Immunotherapy in Lung Cancer

Tracey Evans, MD
Published: Friday, Mar 24, 2017



Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Although immunotherapy is showing promise in lung cancer, it is not for every patient. Dealing with the disappointment from both the patients and their families can be very difficult, says Evans.

Also, pseudo-progression is sometimes seen in the first-line setting with immune-based agents in this disease, adds Evans. If this seems to be occurring, switching to chemotherapy may be a viable option.
 


Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Although immunotherapy is showing promise in lung cancer, it is not for every patient. Dealing with the disappointment from both the patients and their families can be very difficult, says Evans.

Also, pseudo-progression is sometimes seen in the first-line setting with immune-based agents in this disease, adds Evans. If this seems to be occurring, switching to chemotherapy may be a viable option.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x